{"keywords":["anaplastic lymphoma kinase","c-ros1","crizotinib","echinoderm microtubule-associated protein-like 4","met/hepatocyte growth factor receptor","non-small-cell lung cancer"],"meshTags":["Animals","Carcinoma, Non-Small-Cell Lung","Gene Rearrangement","Humans","Lung Neoplasms","Molecular Targeted Therapy","Neoplasm Metastasis","Oncogene Proteins, Fusion","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Survival Rate"],"meshMinor":["Animals","Carcinoma, Non-Small-Cell Lung","Gene Rearrangement","Humans","Lung Neoplasms","Molecular Targeted Therapy","Neoplasm Metastasis","Oncogene Proteins, Fusion","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Survival Rate"],"genes":["echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase"],"publicationTypes":["Journal Article","Review"],"abstract":"The US FDA granted approval for crizotinib as the first-line treatment for patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013. Crizotinib is a customized and improved therapeutic option for patients with non-small-cell lung cancer that enhances overall survival without increasing toxicity. In the future, new targeted therapies may achieve additional indications for treating patients with lung cancer. This article summarizes data from crizotinib studies.","title":"Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.","pubmedId":"25797684"}